Antidepressant GLYX-13 Shows Promise in Phase IIa
By Marie Powers
Thursday, December 6, 2012
Privately held Naurex Inc. posted impressive Phase IIa results for lead antidepressant compound, GLYX-13, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, showing statistically significant reductions in depression scores in patients who had failed treatment with one or more antidepressant agents.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.